Repurposing Available Anti-inflammatory and Immunomodulating Agents for Cardiovascular Risk Management: A Call for Submissions to Current Clinical Pharmacology

Author(s): Arduino A. Mangoni*, Gian L. Erre

Journal Name: Current Clinical Pharmacology

Volume 15 , Issue 1 , 2020

Become EABM
Become Reviewer

[1]
Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: A systematic analysis for theGlobal Burden of Disease Study 2016. Lancet 2017; 390: 1151-210.
[2]
Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 2017; 70: 1-25.
[3]
Huynh T, Montigny M, Iftikhar U, et al. recurrent cardiovascular events in survivors of myocardial infarction with ST-segment elevation (from the AMI-QUEBEC study). Am J Cardiol 2018; 121: 897-902.
[4]
Guedeney P, Claessen BE, Kalkman DN, et al. Residual inflammatory risk in patients with low LDL cholesterol levels undergoing percutaneous coronary intervention. J Am Coll Cardiol 2019; 73: 2401-9.
[5]
Aday AW, Ridker PM. Targeting residual inflammatory risk: A shifting paradigm for atherosclerotic disease. Front Cardiovasc Med 2019; 6: 16.
[6]
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
[7]
Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: Current therapeutic approaches. Eur Heart J 2016; 37: 1723-32.
[8]
Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108: 1362-70.
[9]
Mangoni AA, Zinellu A, Sotgia S, Carru C, Piga M, Erre GL. Protective effects of methotrexate against proatherosclerotic cytokines: A review of the evidence. Mediators Inflamm 2017; 2017 9632846
[10]
Mangoni AA, Tommasi S, Zinellu A, et al. Repurposing existing drugs for cardiovascular risk management: A focus on methotrexate. Drugs Context 2018; 7 212557
[11]
Mangoni AA, Tommasi S, Zinellu A, et al. Methotrexate and vasculoprotection: Mechanistic insights and potential therapeutic applications in old age. Curr Pharm Des 2019; 25: 4175-84.
[12]
Thompson PL, Nidorf SM. Colchicine: An affordable anti-inflammatory agent for atherosclerosis. Curr Opin Lipidol 2018; 29: 467-73.
[13]
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med 2019; 381: 2497-505.
[14]
Floris A, Piga M, Mangoni AA, Bortoluzzi A, Erre GL, Cauli A. Protective effects of hydroxychloroquine against accelerated atherosclerosis in Systemic Lupus Erythematosus. Mediators Inflamm 2018; 2018 3424136
[15]
Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: A systematic review and meta-analysis. Ann Rheum Dis 2018; 77: 98-103.
[16]
Sharma TS, Wasko MC, Tang X, et al. Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients. J Am Heart Assoc 2016; 5(1) e002867
[17]
Mangoni AA, Baghdadi LR, Shanahan EM, et al. Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study. Ther Adv Musculoskelet Dis 2017; 9: 213-29.
[18]
Woodman RJ, Baghdadi LR, Shanahan ME, Mangoni AA. The temporal relationship between arterial stiffening and blood pressure is modified by methotrexate treatment in patients with rheumatoid Arthritis. Front Physiol 2017; 8: 593.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Page: [2 - 3]
Pages: 2
DOI: 10.2174/157488471501200319150358

Article Metrics

PDF: 19
HTML: 4
EPUB: 1
PRC: 1